Mainz Biomed Yönetim

Yönetim kriter kontrolleri 0/4

Mainz Biomed CEO'su Guido Baechler, Jul2021 tarihinde atandı, in görev süresi 3.33 yıldır. şirketin hisselerinin 2.94% doğrudan sahiptir ve bu hisselerin değeri $ 156.11K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 2.9 yıldır.

Anahtar bilgiler

Guido Baechler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.3yrs
CEO sahipliği	2.9%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Guido Baechler (59 yo)

3.3yrs

Görev süresi

Mr. Guido Baechler serves as Chief Executive Officer at Mainz Biomed N.V. since July 1, 2021 and has been its Executive Director since July 2021. Mr. Baechler served as Chief Executive Officer at SummerBio...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Guido Baechler	CEO & Executive Director	3.3yrs	Veri yok	2.94% $ 156.1k
William Caragol	Chief Financial Officer	3.3yrs	Veri yok	0.83% $ 44.1k
Christopher Von Torne	Chief Operating Officer	1.8yrs	Veri yok	0.026% $ 1.4k
Frank Krieg-Schneider	Chief Technology Officer	1.8yrs	Veri yok	0.046% $ 2.4k
Moritz Eidens	Chief Science Officer & Executive Director	3.2yrs	Veri yok	4.4% $ 233.7k
Stefan Erlach	Head of Human Resources	1.8yrs	Veri yok	Veri yok
Philipp Freese	Chief Business Officer	1.8yrs	Veri yok	1.41% $ 75.1k

1.8yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: MYNZ 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Guido Baechler	CEO & Executive Director	3.3yrs	Veri yok	2.94% $ 156.1k
Moritz Eidens	Chief Science Officer & Executive Director	16.4yrs	Veri yok	4.4% $ 233.7k
Hans Hekland	Independent Non-Executive Director	3yrs	Veri yok	2.8% $ 148.8k
Gregory Tibbitts	Independent Non-Executive Director	1.9yrs	Veri yok	0.14% $ 7.3k
Heinrich Dreismann	Independent Non-Executive Chairman	1.9yrs	Veri yok	0.34% $ 18.3k
Soren Thestrup-Nielsen	Member of Strategic Advisory Board	3yrs	Veri yok	Veri yok
Michele Pedrocchi	Member of Strategic Advisory Board	2.8yrs	Veri yok	Veri yok
Rainer Metzger	Member of Strategic Advisory Board	2.8yrs	Veri yok	Veri yok
Karen Richards	Member of Strategic Advisory Board	no data	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MYNZ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Mainz Biomed Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Mainz Biomed N.V., Annual General Meeting, May 31, 2024

Mainz Biomed N.V., Annual General Meeting, Jun 28, 2023

Mainz Biomed B.V. Announces Management Changes

High number of new and inexperienced directors

Mainz Biomed B.V. Appoints Dr. Douglas Rex to its Medical Advisory Board

Mainz Biomed B.V. Appoints D. Kim Turgeon to Its Medical Advisory Board

Recent updates

Mainz Biomed N.V. has filed a Follow-on Equity Offering in the amount of $9.2 million.

New major risk - Shareholder dilution

First half 2024 earnings released: US$0.49 loss per share (vs US$1.00 loss in 1H 2023)

Mainz Biomed Reports Increased Demand for Enhanced Coloalert, Existing Partners to Transition to New Version

Mainz Biomed N.V. Announces FDA Trials in 2025

Price target decreased by 33% to US$2.00

Mainz Biomed N.V. Launches Enhanced Coloalert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Mainz Biomed N.V. Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Mainz Biomed N.V. Presents an Analysis from Its eAArly Detect Study At Digestive Disease Week

Mainz Biomed N.V., Annual General Meeting, May 31, 2024

Consensus revenue estimates fall by 48%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mainz Biomed N.V. Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Consensus revenue estimates decrease by 28%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mainz Biomed N.V. has completed a Follow-on Equity Offering.

Mainz Biomed N.V. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Mainz Biomed N.V. Presents Results of Colofuture Study

Mainz Biomed N.V. Announces Positive Topline Results from its ColoFuture Study

Mainz Biomed Announces Live Launch of ColoAlert with testDNA Laboratory in Poland

Consensus revenue estimates fall by 19%

New major risk - Revenue and earnings growth

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Mainz Biomed Announces Live Launch of ColoAlert with Marylebone Laboratory in the United Kingdom

Mainz Biomed N.V. announced that it has received $5.06 million in funding from Yorkville Advisors Global LP

Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper

Mainz Biomed N.V., Annual General Meeting, Jun 28, 2023

Mainz Biomed B.V. Launches Corporate Health Program in Germany for ColoAlert

Mainz Biomed B.V. Announces Management Changes

Mainz Biomed B.V. Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

Mainz Biomed Announces U.S. Extension of Colofuture Study to Evaluate Integration of Novel Mrna Biomarkers into Coloalert

High number of new and inexperienced directors

Mainz Biomed B.V. Appoints Dr. Douglas Rex to its Medical Advisory Board

Mainz Biomed GAAP EPS of -$0.91, revenue of $0.24M beats by $0.14M

Mainz Biomed B.V. Appoints D. Kim Turgeon to Its Medical Advisory Board

Mainz Biomed N.V. and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

Mainz Biomed stock rises 22% on launch of colorectal cancer test in Italy, UAE

High number of new and inexperienced directors

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

Mainz Biomed B.V. Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Mainz Biomed B.V. Successfully Completes Conformity Assessment to Ivdr Achieving New Level of Eu Regulatory Compliance

Mainz Biomed B.V., Annual General Meeting, Jun 28, 2022

Mainz Biomed Provides Product Development Update on Pancalert

Mainz Biomed B.V. announced delayed 20-F filing

Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer

Mainz Biomed Completes Successful Pre-Submission Process with the U.S Fda for Coloalert’S Pivotal Clinical Trial

Mainz Biomed Provides U.S. Regulatory Review Update for Coloalert

Mainz Biomed B.V. Announces the Appointment of Dr. Rainer Metzger to Its Strategic Advisory Board

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

Mainz Biomed: Sharp Appreciation In Value Since IPO

Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic

No independent directors

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş